Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BALANCE: Gemigliptin/Rosuvastatin FDC in T2DM and Dyslipidemia
NCT02126358Phase 3Completed
- Sponsor
- LG Chem
- Start
- May 2014
- Primary completion
- Mar 2016
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of gemigliptin, rosuvastatin in type 2 diabetes mellitus (T2DM), dyslipidemia, sponsored by LG Chem. Started May 2014; status: completed.
02
Drugs
gemigliptinrosuvastatin
03
Conditions
type 2 diabetes mellitus (T2DM)dyslipidemia
Beyond the preview
Go deeper on NCT02126358.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02126358.